drugset

drugset / Trial / NCT05525767

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

NCT05525767 ↗

Phase 4 Recruiting 75 enrolled Hebei Medical University Fourth Hospital

NaSingle-groupOpen-labelTreatment

Summary

This is an prospective, multicenter, single-arm clinical study.

Timeline

Start: 2022-03-31
Primary completion: 2026-10-31
Completion: 2028-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	10 mg/kg	—

Indications